Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence.
Rosa Escudero-SanchezAntonio Ramos-MartínezAntonio F Caballero-BermejoBeatriz Díaz-PollánGuillermo Ruiz-CarrascosoMaría Olmedo SamperioPatricia Muñoz GarcíaPaloma Merino AmadorFernando González RomoOriol Martín SegarraGema Navarro JiménezLaura Del Campo AlbendeaAlfonso Muriel GarcíaJavier CoboPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
We observed that patients treated with bezlotoxumab in a real-world setting during a first episode of CDI having high risk of recurrence, presented low rate of recurrence. However, a significant difference in recurrence could not be proved in comparison to the controls. We did not detect any other safety concerns.
Keyphrases